Department of Respirology, Chiba University Graduate School of Medicine, Chiba, 260-8670, Japan.
Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, 260-8670, Japan.
Mol Psychiatry. 2022 Apr;27(4):1898-1907. doi: 10.1038/s41380-021-01432-3. Epub 2022 Jan 7.
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of prophylactic and therapeutic drugs for persons infected with the virus. Drug repurposing for the COVID-19 pandemic has received particular attention. Increasing clinical data suggest that antidepressant use in early-stage subjects with COVID-19 might be associated with a reduced risk of intubation or death. Among the antidepressants, fluvoxamine is the most attractive drug for mild to moderate subjects with COVID-19. In this article, we review the mechanisms of action (i.e., serotonin transporter, sigma-1 receptor, and acid sphingomyelinase) of fluvoxamine for COVID-19. Furthermore, we discuss a possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders (i.e., autism spectrum disorder and schizophrenia) in offspring.
由新型严重急性呼吸系统综合症冠状病毒 2 （SARS-CoV-2）引起的持续的 2019 年冠状病毒病（COVID-19）大流行加速了预防和治疗感染该病毒的人的药物的发现。药物重新用于 COVID-19 大流行受到了特别关注。越来越多的临床数据表明，在 COVID-19 的早期患者中使用抗抑郁药可能与插管或死亡的风险降低有关。在抗抑郁药中，氟伏沙明是治疗 COVID-19 轻度至中度患者最具吸引力的药物。在本文中，我们回顾了氟伏沙明对 COVID-19 的作用机制（即 5-羟色胺转运体、sigma-1 受体和酸性鞘磷脂酶）。此外，我们还讨论了母亲 COVID-19 感染与后代神经精神疾病（即自闭症谱系障碍和精神分裂症）风险之间的可能联系。
